Vanguard Group Inc. Lowers Position in Prestige Consumer Healthcare Inc. $PBH

Vanguard Group Inc. decreased its position in Prestige Consumer Healthcare Inc. (NYSE:PBH) by 2.5% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 5,492,748 shares of the company’s stock after selling 140,238 shares during the quarter. Vanguard Group Inc. owned approximately 11.16% of Prestige Consumer Healthcare worth $342,747,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in PBH. First Horizon Corp purchased a new position in Prestige Consumer Healthcare during the third quarter worth about $32,000. Hantz Financial Services Inc. raised its stake in shares of Prestige Consumer Healthcare by 373.6% in the third quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock valued at $43,000 after buying an additional 538 shares during the period. Elevation Point Wealth Partners LLC purchased a new position in shares of Prestige Consumer Healthcare during the 2nd quarter valued at $46,000. First Horizon Advisors Inc. grew its stake in shares of Prestige Consumer Healthcare by 294.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after acquiring an additional 447 shares during the period. Finally, Geneos Wealth Management Inc. increased its holdings in Prestige Consumer Healthcare by 92.8% in the 1st quarter. Geneos Wealth Management Inc. now owns 559 shares of the company’s stock worth $48,000 after acquiring an additional 269 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

Prestige Consumer Healthcare Price Performance

Shares of NYSE:PBH opened at $69.30 on Friday. Prestige Consumer Healthcare Inc. has a one year low of $57.25 and a one year high of $90.04. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.11 and a quick ratio of 1.93. The firm has a market capitalization of $3.28 billion, a price-to-earnings ratio of 18.33, a PEG ratio of 2.21 and a beta of 0.43. The company’s fifty day moving average price is $65.26 and its 200-day moving average price is $63.48.

Prestige Consumer Healthcare (NYSE:PBH) last released its earnings results on Thursday, February 5th. The company reported $1.14 EPS for the quarter, missing analysts’ consensus estimates of $1.16 by ($0.02). Prestige Consumer Healthcare had a net margin of 16.90% and a return on equity of 12.02%. The firm had revenue of $283.44 million during the quarter, compared to the consensus estimate of $286.93 million. During the same period in the prior year, the company earned $1.22 EPS. The firm’s revenue was down 2.4% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.540-4.540 EPS. On average, equities research analysts anticipate that Prestige Consumer Healthcare Inc. will post 4.5 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Prestige Consumer Healthcare news, VP Jeffrey Zerillo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, February 11th. The stock was sold at an average price of $65.93, for a total value of $65,930.00. Following the completion of the sale, the vice president owned 41,048 shares in the company, valued at approximately $2,706,294.64. This trade represents a 2.38% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. 1.40% of the stock is owned by insiders.

Prestige Consumer Healthcare News Roundup

Here are the key news stories impacting Prestige Consumer Healthcare this week:

• Positive Sentiment: Bleakley Financial Group reported a new purchase of 10,912 PBH shares (~$681,000), signaling fresh institutional buying interest in the stock. Bleakley Investment
• Positive Sentiment: Zacks bumped a few quarterly estimates: Q4 2026 was raised to $1.59 (from $1.54), Q3 2027 to $1.21 (from $1.20) and Q4 2027 to $1.32 (from $1.26) — small upside revisions that suggest pockets of strength in certain quarters.
• Neutral Sentiment: Zacks Research continues to carry a “Hold” rating on PBH even as it updates estimates; the firm’s commentary so far is a recalibration of numbers rather than a rating change. Consensus full‑year EPS referenced by Zacks remains near $4.50 for the current year.
• Negative Sentiment: Zacks pared several near‑term and fiscal forecasts, which is the main driver of downward pressure: Q1 2027 EPS cut to $1.09 (from $1.24), Q1 2028 to $1.14 (from $1.26), Q2 2028 to $1.30 (from $1.33), Q3 2028 to $1.26 (from $1.28), FY2027 to $4.77 (from $4.84) and FY2028 to $5.06 (from $5.19). Those trims signal slower expected earnings growth and likely explain why the stock is underperforming today.

Analysts Set New Price Targets

PBH has been the subject of a number of research reports. Zacks Research upgraded shares of Prestige Consumer Healthcare from a “strong sell” rating to a “hold” rating in a research report on Monday, November 10th. Jefferies Financial Group cut their price objective on shares of Prestige Consumer Healthcare from $70.00 to $66.00 and set a “hold” rating for the company in a report on Friday, January 30th. Weiss Ratings reiterated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Thursday, January 22nd. Finally, Canaccord Genuity Group lowered their target price on shares of Prestige Consumer Healthcare from $100.00 to $88.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Three investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Hold” and an average price target of $80.60.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).